Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma 54179060LYM2003 (Nick Name: IVORY Study)

NCT02670616 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02670616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02670616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma 54179060LYM2003 (Nick Name: IVORY Study)
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2016
Completion date
October 31, 2020
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr virus-positive diffuse large b-cell lymphoma